A substantial proportion of patients who discontinue GLP-1 receptor agonist medications for type 2 diabetes eventually resume treatment, according to recent analysis of patient treatment patterns. The finding challenges assumptions about permanent discontinuation and suggests that newer formulations may improve medication persistence, though gastrointestinal side effects remain a leading reason patients initially abandon therapy.
Key takeaways
- A significant proportion of patients who stop GLP-1 drugs such as Ozempic and Victoza later restart treatment
- Newer GLP-1 medications demonstrate improved persistence rates compared to older formulations
- Gastrointestinal adverse effects—nausea, vomiting, and diarrhoea—remain the primary driver of initial discontinuation
- Treatment re-initiation patterns suggest that side effect resolution or dose adjustment encourages resumption of therapy
Why Patients Stop and Restart GLP-1 Therapy
Primary reasons for initial discontinuation and likelihood of treatment resumption
Source: Analysis of GLP-1 treatment patterns | Georgian Medical Journal News
Discontinuation Rates Mask Substantial Treatment Re-initiation
Previous research documented that discontinuation rates for GLP-1 receptor agonists are considerable, with many patients abandoning therapy within the first year. However, this narrative obscures a critical finding: research into treatment patterns shows that a large proportion of those who stop therapy later return to it, suggesting that “discontinuation” is not always permanent. This distinction has important implications for understanding real-world medication effectiveness and for designing interventions to support sustained glucose control.
The pattern of temporary discontinuation followed by re-initiation may reflect patients’ experience with side effects that improve with continued therapy, dose adjustments, or resolution over time. Understanding why patients return—or why some do not—remains a crucial gap in diabetes care management.
Gastrointestinal Adverse Effects Drive Initial Treatment Cessation
Nausea, vomiting, and diarrhoea remain the most frequently reported reasons for GLP-1 medication discontinuation, with these gastrointestinal symptoms affecting the majority of patients who stop treatment. These effects typically emerge within the first weeks of therapy and can persist for several months, creating a critical window during which many patients abandon medication without knowing whether symptoms would eventually subside.
Cost and insurance barriers represent the second major driver of discontinuation, while some patients prefer oral formulations over injectable delivery systems. Together, these factors suggest that discontinuation is often reversible: when gastrointestinal symptoms resolve, when financial access improves, or when patients perceive renewed clinical benefit, many restart therapy.
Newer Medications Show Improved Persistence, Suggesting Formulation Matters
More recent GLP-1 formulations, including tirzepatide (a dual GIP/GLP-1 receptor agonist), demonstrate longer median time to discontinuation compared to older agents such as liraglutide, according to patient cohort data. This improvement may reflect refinements in dosing schedules, delivery mechanisms, or improved patient education about side effect management. Comparative analyses of medication persistence show that newer agents may keep patients engaged in therapy, though long-term comparative effectiveness data remain limited.
The role of drug formulation in persistence highlights an underappreciated lever for improving treatment outcomes: when patients experience fewer side effects or more convenient dosing schedules, they remain on therapy longer and are less likely to discontinue in the first place.
Cost, Access, and Equity in GLP-1 Treatment Pathways
Beyond medication efficacy and tolerability, financial barriers loom large in treatment discontinuation patterns. High out-of-pocket costs, insurance coverage gaps, and prior authorization requirements force many patients to interrupt or abandon therapy despite clinical benefit. This is particularly concerning in the context of type 2 diabetes, where affected populations often face the greatest socioeconomic barriers to continuous care.
In low-resource settings and among uninsured populations in high-income countries, cost-driven discontinuation represents a major equity challenge, as GLP-1 drugs remain prohibitively expensive for many patients. Addressing these barriers—through insurance policy reform, biosimilar availability, or tiered pricing—could reduce the initial discontinuation rate and keep more patients engaged with diabetes treatment from the outset.
A significant proportion of patients who discontinue GLP-1 therapy for type 2 diabetes eventually return to treatment, suggesting that discontinuation may be temporary rather than permanent and that side effect management and cost support are critical intervention points.
— Based on analysis of GLP-1 treatment patterns and patient cohort data
What this means
Frequently asked questions
If I stop taking my GLP-1 medication, can I restart it later?
Yes. The finding that many patients who discontinue GLP-1 therapy later resume treatment suggests that restarting is both feasible and common in clinical practice. Discuss your reasons for stopping—whether side effects, cost, or other factors—with your doctor, as addressing the underlying barrier may make resumption successful. You may also benefit from dose reduction or a different formulation when you restart.
How long do gastrointestinal side effects from GLP-1 drugs typically last?
Nausea, vomiting, and diarrhoea from GLP-1 medications most commonly emerge in the first 1-4 weeks and often improve substantially by 8-12 weeks as the body adapts to the medication. However, some patients experience persistent symptoms. Slower dose escalation, smaller meal portions, and ginger or anti-emetic medications may help manage symptoms while your body adjusts. If symptoms persist beyond 12 weeks, discuss alternative agents or doses with your clinician.
Why do newer GLP-1 drugs seem to have better persistence than older ones?
Newer formulations such as tirzepatide offer weekly dosing (versus daily for liraglutide), which improves convenience and adherence. Some newer agents also have slightly different side effect profiles or may work through dual mechanisms (like tirzepatide’s GIP/GLP-1 activity), which some patients tolerate better. Additionally, improved patient education and clinician familiarity with managing side effects at treatment initiation support longer persistence with newer medications.
The emerging picture of GLP-1 treatment trajectories—marked by initial discontinuation, side effect burden, and subsequent re-initiation—suggests that discontinuation rates alone do not capture the true treatment experience. Future quality improvement initiatives should focus on reducing the initial discontinuation rate through better side effect counseling and support during the critical first weeks, expanding financial access to prevent cost-driven abandonment, and ensuring that patients who benefit from GLP-1 therapy can afford to remain on it continuously. See more on clinical treatment updates and explore pharmacy and prescribing guidance on GMJ News.
Source: Most people who stop GLP-1 drugs like Ozempic eventually return, Science Daily (June 2026)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
